DB:M3V

Stock Analysis Report

MeVis Medical Solutions

Executive Summary

MeVis Medical Solutions AG develops, markets, and sells software for analyzing and evaluating image data to equipment manufacturers of medical devices and providers of medical IT platforms in the United States and Europe.


Snowflake Analysis

Flawless balance sheet and undervalued.

Share Price & News

How has MeVis Medical Solutions's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: M3V has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

6.1%

M3V

1.7%

DE Healthcare Services

0.06%

DE Market


1 Year Return

-4.9%

M3V

32.2%

DE Healthcare Services

14.8%

DE Market

Return vs Industry: M3V underperformed the German Healthcare Services industry which returned 33% over the past year.

Return vs Market: M3V underperformed the German Market which returned 17.1% over the past year.


Shareholder returns

M3VIndustryMarket
7 Day6.1%1.7%0.06%
30 Day8.3%2.8%1.8%
90 Day5.4%12.7%7.1%
1 Year-1.9%-4.9%33.3%32.2%18.4%14.8%
3 Year-16.3%-22.3%67.7%63.3%17.4%7.0%
5 Year92.0%72.2%196.3%183.2%27.9%10.4%

Price Volatility Vs. Market

How volatile is MeVis Medical Solutions's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is MeVis Medical Solutions undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: M3V (€31) is trading below our estimate of fair value (€83.98)

Significantly Below Fair Value: M3V is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: M3V is good value based on its PE Ratio (7.3x) compared to the Healthcare Services industry average (12.7x).

PE vs Market: M3V is good value based on its PE Ratio (7.3x) compared to the German market (20.6x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate M3V's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: M3V is good value based on its PB Ratio (1.5x) compared to the DE Healthcare Services industry average (2.6x).


Next Steps

Future Growth

How is MeVis Medical Solutions forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MeVis Medical Solutions has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has MeVis Medical Solutions performed over the past 5 years?

13.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: M3V has high quality earnings.

Growing Profit Margin: M3V's current net profit margins (45.4%) are higher than last year (41.1%).


Past Earnings Growth Analysis

Earnings Trend: M3V's earnings have grown by 13.4% per year over the past 5 years.

Accelerating Growth: M3V's earnings growth over the past year (15.3%) exceeds its 5-year average (13.4% per year).

Earnings vs Industry: M3V earnings growth over the past year (15.3%) underperformed the Healthcare Services industry 27.6%.


Return on Equity

High ROE: M3V's Return on Equity (20.7%) is considered high.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is MeVis Medical Solutions's financial position?


Financial Position Analysis

Short Term Liabilities: M3V's short term assets (€10.5M) exceed its short term liabilities (€3.6M).

Long Term Liabilities: M3V's short term assets (€10.5M) exceed its long term liabilities (€327.0K).


Debt to Equity History and Analysis

Debt Level: M3V is debt free.

Reducing Debt: M3V has not had any debt for past 5 years.

Debt Coverage: M3V has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: M3V has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: M3V has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if M3V's debt is covered by short term assets.


Next Steps

Dividend

What is MeVis Medical Solutions's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

company0%marketbottom25%1.4%markettop25%3.5%industryaverage1.5%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate M3V's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate M3V's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if M3V's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if M3V's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: M3V is not paying a notable dividend for the German market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of M3V's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of MeVis Medical Solutions's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average board tenure


CEO

Marcus Kirchhoff (50yo)

7.8yrs

Tenure

€248,834

Compensation

Mr. Marcus Kirchhoff has been the Chief Executive Officer, Chairman of the Board and Member of the Executive Board at MeVis Medical Solutions AG since March 1, 2012. Mr. Kirchhoff serves as Vice President  ...


CEO Compensation Analysis

Compensation vs Market: Marcus's total compensation ($USD276.82K) is below average for companies of similar size in the German market ($USD425.50K).

Compensation vs Earnings: Marcus's compensation has been consistent with company performance over the past year.


Board Age and Tenure

2.8yrs

Average Tenure

Experienced Board: M3V's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Marcus Kirchhoff (50yo)

    Chairman of the Executive Board & CEO

    • Tenure: 7.8yrs
    • Compensation: €248.83k

Board Members

  • Clarence Verhoef (64yo)

    Deputy Chairman of Supervisory Board

    • Tenure: 2.8yrs
  • Matt Lowell

    Member of the Supervisory Board

    • Tenure: 2.8yrs
  • Kim Honeysett (48yo)

    Chairperson of Supervisory Board

    • Tenure: 2.8yrs

Company Information

MeVis Medical Solutions AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MeVis Medical Solutions AG
  • Ticker: M3V
  • Exchange: DB
  • Founded: 1992
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: €57.148m
  • Shares outstanding: 1.82m
  • Website: https://www.mevis.de

Number of Employees


Location

  • MeVis Medical Solutions AG
  • Caroline-Herschel-Strasse 1
  • Bremen
  • Bremen
  • 28359
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
M3VDB (Deutsche Boerse AG)YesRegistered SharesDEEURNov 2007
M3VXTRA (XETRA Trading Platform)YesRegistered SharesDEEURNov 2007
0HI7LSE (London Stock Exchange)YesRegistered SharesGBEURNov 2007

Biography

MeVis Medical Solutions AG develops, markets, and sells software for analyzing and evaluating image data to equipment manufacturers of medical devices and providers of medical IT platforms in the United States and Europe. The company's clinical focuses are image-based early detection and diagnosis of epidemiologically important diseases, such as breast, lung, prostate, and colon cancers, as well as neurological disorders. It operates in two segments, Digital Mammography and Other Diagnostics. The Digital Mammography segment develops and markets software products, which support breast diagnostic imaging and intervention. This segment also offers software applications for digital mammography, such as ultrasound, magnetic resonance imaging, and tomosynthesis. The Other Diagnostics segment provides digital radiology products, including magnetic resonance imaging and computer tomography for diseases, such as lung, prostate, and intestinal disorders, as well as general image-based analysis and diagnostics of radiology images. Its services are also used for lung diagnostics and general analysis of MR-image data; and technical visualization, which are used in training, for publication, presentations, and research purposes. This segment also provides interactive online training to enhance the diagnostic capabilities of clinical end customers. The company was founded in 1992 and is based in Bremen, Germany. MeVis Medical Solutions AG operates as a subsidiary of Varex Imaging Deutschland AG. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/01/17 21:03
End of Day Share Price2020/01/17 00:00
Earnings2019/06/30
Annual Earnings2018/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.